Nymox Pharmaceutical Corporation Stock Nasdaq
Equities
CA67076P1027
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2021 | - | Sales 2022 | - | Capitalization | 29.51M 40.2M |
---|---|---|---|---|---|
Net income 2021 | -12M -16.35M | Net income 2022 | -6M -8.18M | EV / Sales 2021 | - |
Net cash position 2021 | 439K 598K | Net cash position 2022 | 1.23M 1.68M | EV / Sales 2022 | - |
P/E ratio 2021 |
-8.5
x | P/E ratio 2022 |
-4.39
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 57.95% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Averback
CEO | Chief Executive Officer | 73 | 95-05-29 |
Patrick Doody
BRD | Director/Board Member | - | 23-07-11 |
Director/Board Member | - | 23-03-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
David S. Morse
BRD | Director/Board Member | 67 | 06-06-07 |
Paul Averback
CEO | Chief Executive Officer | 73 | 95-05-29 |
Director/Board Member | 88 | 15-06-30 |
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |